- Home
- LGND vs LEGN Comparison
LGND vs LEGN Comparison
Compare LGND & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGND | LEGN |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LGND | LEGN |
|---|---|---|
| Price | $306.50 | $18.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $256.29 | $61.33 |
| AVG Volume (30 Days) | 172.3K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2886.36 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $141,102,000.00 | N/A |
| Revenue This Year | $1.25 | $42.68 |
| Revenue Next Year | $19.41 | $30.52 |
| P/E Ratio | $192.70 | ★ N/A |
| Revenue Growth | ★ 29.48 | N/A |
| 52 Week Low | $175.89 | $16.24 |
| 52 Week High | $326.63 | $37.50 |
Technical Indicators
Market Signals| Indicator | LGND | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 45.35 |
| Support Level | $286.99 | $17.81 |
| Resistance Level | $322.06 | $19.36 |
| Average True Range (ATR) | 9.45 | 0.80 |
| MACD | 3.06 | 0.15 |
| Stochastic Oscillator | 77.12 | 66.89 |
Price Performance
Historical ComparisonAbout LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.